These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 17427619)

  • 1. Parkinson's disease.
    Clarke CE; Moore AP
    Am Fam Physician; 2007 Apr; 75(7):1045-8. PubMed ID: 17427619
    [No Abstract]   [Full Text] [Related]  

  • 2. Levodopa: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S23-37. PubMed ID: 12211137
    [No Abstract]   [Full Text] [Related]  

  • 3. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reply to Jack E. Riggs' "Deprenyl, excess mortality, and epidemiological traps". Parkinson's Disease Research Group of the United Kingdom.
    Head J; Ben-Shlomo Y; Lees AJ
    Clin Neuropharmacol; 1998; 21(4):265-6. PubMed ID: 9704171
    [No Abstract]   [Full Text] [Related]  

  • 5. Is pathological gambling in Parkinson's disease reduced by amantadine?
    Lee JY; Kim HJ; Jeon BS
    Ann Neurol; 2011 Jan; 69(1):213-4; author reply 214-5. PubMed ID: 21280095
    [No Abstract]   [Full Text] [Related]  

  • 6. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of L-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease.
    Mestre DR; Blin O; van den Brand CL; Azulay JP; Serratrice G
    Adv Neurol; 1996; 69():503-11. PubMed ID: 8615172
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of levodopa on word intelligibility in Parkinson's disease.
    De Letter M; Santens P; Van Borsel J
    J Commun Disord; 2005; 38(3):187-96. PubMed ID: 15748723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa therapeutics for Parkinson's disease: new developments.
    LeWitt PA
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating Parkinson's disease.
    Standaert D
    Health News; 1998 Nov; 4(14):1-2. PubMed ID: 9825707
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of depression in idiopathic Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S112-9. PubMed ID: 12211151
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
    Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
    BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
    [No Abstract]   [Full Text] [Related]  

  • 13. Modern treatment of Parkinson's disease.
    Pearce JM
    Br J Hosp Med; 1987 Jan; 37(1):59, 61, 64-6. PubMed ID: 3545340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep brain stimulation for Parkinson's disease.
    Med Lett Drugs Ther; 2009 Apr; 51(1309):26-7. PubMed ID: 19343007
    [No Abstract]   [Full Text] [Related]  

  • 15. Levodopa therapy for Parkinson's disease: challenges and future prospects.
    Olanow CW; Lees A; Obeso J
    Mov Disord; 2008; 23 Suppl 3():S495-6. PubMed ID: 18781670
    [No Abstract]   [Full Text] [Related]  

  • 16. Levodopa and the progression of Parkinson's disease.
    Walton-Hadlock JL
    N Engl J Med; 2005 Mar; 352(13):1386; author reply 1386. PubMed ID: 15800240
    [No Abstract]   [Full Text] [Related]  

  • 17. Malignant melanoma in early Parkinson's disease: the DATATOP trial.
    Constantinescu R; Romer M; Kieburtz K;
    Mov Disord; 2007 Apr; 22(5):720-2. PubMed ID: 17373726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing clinical outcomes in residents with Parkinson's disease. Introduction.
    Libow LS
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):3. PubMed ID: 17948615
    [No Abstract]   [Full Text] [Related]  

  • 19. [Disturbance of micturition in Parkinson's disease].
    Sakakibara R; Uchiyama T; Yoshiyama M; Hattori T
    No To Shinkei; 2001 Nov; 53(11):1009-14. PubMed ID: 11761908
    [No Abstract]   [Full Text] [Related]  

  • 20. [ What drug strategies are advisable for patients with advanced-stage Parkinson's].
    Brefel-Courbon C
    Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():120-59. PubMed ID: 10916046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.